华蟾素治疗难治性血小板减少性紫癜有效性及安全性  

Efficiency and safety of cinobufacini in treating refractory thrombocytopenic purpura

作　　者：蓝海[1] 古学奎[1] 陈志雄[1] 胡莉文[1] 刘安平[1] 

机构地区：[1]广州中医药大学第一附属医院血液科,广州510407

出　　处：《吉林中医药》2014年第4期385-387,共3页Jilin Journal of Chinese Medicine

基　　金：广东省中医药管理局课题(20121216);广东省科技计划项目(2012b031800194)

摘　　要：目的华蟾素治疗难治性血小板减少性紫癜有效性及安全性探讨。方法本研究收集2012年1月—2013年1月期间广州中医药大学一附院血液科病人60例。随机分为试验组30例(华蟾素)与对照组30例(达那唑)。对照组给予达那唑,试验组给予华蟾素(10 mL/次,1次/d,静注),连用12周。结果经治疗试验组CD4+T细胞(33.5±4.1)、CD4+CD25+Treg/CD4+细胞(11.4±3.4)表达水平,与治疗前(17.2±3.4)(3.0±0.4)及对照组(25.3±6.2)(6.2±1.5)比较,差异有统计学意义(P<0.05)。血小板(112.3±11.7)水平升高明显,与治疗前比较,差异有统计学意义(P<0.05)。总有效率(100.0%)显著高于对照组的总有效率(83.4%),差异有统计学意义(P<0.05),无严重并发症。结论华蟾素改善患者自身反应性T细胞的异常活化,调节T细胞亚群的失调,治疗难治性血小板减少性紫癜,具有较高的有效性及安全性。Objective Study on the efficiency and safety of cinobufacini in treating refractory thrombocytopenic purpura. Methods This study collected 100 cases from hematology department of First Affiliated Hospital of Guangzhou University of Chinese Medicine during the time from January,2012 to January,2013. The cases were randomly divided into the experimental group of 30 cases（ using cinobufacini） and the control group of 30 cases（ using danazol）. The control group and the experimental group were treated with danazol and cinobufacini respectively for 12 weeks. Results After the treatment,the expression of CD4＋ T cells and CD4＋ CD25＋ Treg / CD4＋ cells of experimental group was 33. 5 ± 4. 1 and 11. 4 ± 3. 4. Comparing with the data of experimental group before treatment（ 17. 2 ± 3. 4）（ 3. 0 ± 0. 4） and control group（ 25. 3 ± 6. 2）（ 6. 2 ± 1. 5）,the difference was statistically significant（ P 0. 05）. The amount of blood platelet（ 112. 3 ± 11. 7） increased notably. Comparing with the number before treatment,the difference was statistically significant（ P 0. 05）. Overall response rate（ 100%） was higher than that of the control group（ 83. 4%）,the difference was statistically significant（ P 0. 05）. There was hardly any serious complications. Conclusion Cinobufotalin could improve the abnormal activation of autoimmune T cells of the patients and adjust T cell subgroup. It is safe and effective in the treatment of refractory thrombocytopenic purpura.

关 键 词：华蟾素 血小板减少性紫癜 有效性 安全性 

分 类 号：R259[医药卫生—中西医结合]